Mir G H, Cumming G R
Arch Dis Child. 1971 Feb;46(245):61-5. doi: 10.1136/adc.46.245.61.
A previous report indicated abnormally rapid heart rates in patients with Down's syndrome given atropine, and the possibility of a potentially dangerous idiosyncrasy to atropine in these patients has been raised. The heart rate response to atropine in doses of 30 to 60 μg/kg was studied in 14 children and 11 adults with Down's syndrome, using for control subjects 7 children and 9 adults with mental retardation not due to Down's syndrome. The heart rate response to atropine was similar in the patients with and without Down's syndrome. Peak heart rates occurred at 25 μg/kg of atropine after an initial slowing with 5 to 7 μg/kg. The heart rates of the subjects with Down's syndrome tended to be lower than those of the controls after propranolol was given in addition to the atropine, but the significance of this was not known. Ophthalmic atropine produced a more rapid mydriasis in the Down's syndrome patients, but the degree and duration of the pupillary dilatation was the same as in the control subjects.
先前的一份报告指出，唐氏综合征患者使用阿托品后心率异常加快，有人提出这些患者可能对阿托品存在潜在危险的特异反应。对14名患有唐氏综合征的儿童和11名患有唐氏综合征的成人，研究了剂量为30至60μg/kg的阿托品引起的心率反应，使用7名非唐氏综合征所致智力障碍的儿童和9名非唐氏综合征所致智力障碍的成人作为对照。患有和未患有唐氏综合征的患者对阿托品的心率反应相似。在最初使用5至7μg/kg阿托品使心率减慢后，在使用25μg/kg阿托品时出现心率峰值。除了阿托品外，再给予普萘洛尔后，唐氏综合征患者的心率往往低于对照组，但这一现象的意义尚不清楚。眼科用阿托品使唐氏综合征患者的瞳孔散大更快，但瞳孔散大的程度和持续时间与对照组相同。
